Date: 2016-04-19
Type of information: Construction of new premises
Compound: production site in Geel (Belgium)
Company: Sanofi (France)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On April 19, 2016, Sanofi announced a €300 million investment to expand its site in Geel, Belgium. Through the investment, Sanofi plans to adapt and expand existing production capabilities to support Sanofi's pipeline of monoclonal antibodies. Updates to the existing facility will include the development of new laboratories focused on quality control and manufacturing sciences. Through this latest investment, the facility will add more than 8000 m2 of manufacturing floor space, enabling the site to increase its overall production capacity and diversify to other drugs and therapeutic areas. In support of this expansion, Sanofi intends to recruit and leverage the expertise of highly-skilled biotechnology professionals to fulfill a range of job functions. Sanofi and its specialty care global business unit, Sanofi Genzyme, have already invested €600 million in the Geel site, which began industrial biotech activities in 2001. The site is currently responsible for the global production of a protein therapy for Pompe disease. The protein therapy is produced using cell cultures in large bioreactors, followed by a purification process.
Financial terms:
Latest news:
